Is AZN or TXN cheaper?

On trailing earnings, AZN is cheaper: AZN trades at a 26.92 P/E and TXN at 51.47.

Which has grown faster, AZN or TXN?

Over the past five years, AZN grew revenue faster — AZN at a 16.99% CAGR versus TXN at 3.64%.

Does AZN or TXN pay a bigger dividend?

AZN yields 1.79% and TXN yields 1.87% based on trailing dividends and the latest price.

Is AZN or TXN more profitable?

TXN runs the higher net margin — AZN at 17.19% versus TXN at 29.11%.

Which has been the better investment, AZN or TXN?

Over the past 10-year, TXN delivered the higher annualized total return — AZN at 15.77% versus TXN at 20.37%. Past performance doesn't predict future results.

AstraZeneca PLC (AZN) vs Texas Instruments Incorporated (TXN)

AZN leads on 11 of 17 compared metrics.

A side-by-side comparison of AstraZeneca PLC and Texas Instruments Incorporated across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of June 15, 2026. The ● marks the stronger figure on each row (cheaper multiple, higher margin/return).

Texas Instruments Incorporated

$274.05B

$301.12Technology

Total return — AZN vs TXN

growth of $100 · last 30y

AZN +732.9%TXN +4401.0%TXN compounded faster

Log scale — wide-divergence pair

AZN TXN

AZN vs TXN: by the numbers

•AZN is the larger company ($277.22B vs $274.05B market cap).
•AZN trades at the lower earnings multiple (26.92 vs 51.47 P/E).
•TXN converts more revenue to profit (29.11% vs 17.19% net margin).
•AZN grew revenue faster over the past five years (16.99% vs 3.64% CAGR).
•TXN pays the higher dividend yield (1.87% vs 1.79%).

Which is better, AZN or TXN?

Metric tally: AZN 11 · TXN 6

It depends on what you're optimizing for:

ValueAZN(lower P/E)

GrowthAZN(faster 5Y revenue CAGR)

IncomeTXN(higher dividend yield)

QualityTXN(higher ROIC)

Metrics side by side

Valuation

Metric	AZN	TXN
P/E ratio	26.92●	51.47
Forward P/E	15.33●	33.67
P/S ratio	4.62●	14.93
P/B ratio	5.90●	16.40
PEG ratio	0.14●	7.87
EV / EBITDA	14.92●	34.60
FCF yield	2.89%●	1.35%

Profitability

Metric	AZN	TXN
Gross margin	81.68%●	57.32%
Operating margin	23.69%	35.29%●
Net margin	17.19%	29.11%●
ROE	21.95%	31.99%●
ROIC	13.03%	16.46%●

Dividends

Metric	AZN	TXN
Dividend yield	1.79%	1.87%●
Payout ratio	48.48%	103.12%

Growth (annualized)

Metric	AZN	TXN
Revenue CAGR (5Y)	16.99%●	3.64%
EPS CAGR (5Y)	22.02%●	-2.07%
FCF CAGR (5Y)	15.68%●	-10.12%
Total return CAGR (5Y)	11.03%	12.95%●

Frequently asked

Which is better, AZN or TXN?: It depends on your goal. value: AZN (lower P/E); growth: AZN (faster 5Y revenue CAGR); income: TXN (higher dividend yield); quality: TXN (higher ROIC). Across all compared metrics, AZN leads 11 to 6.
Is AZN or TXN cheaper?: On trailing earnings, AZN is cheaper: AZN trades at a 26.92 P/E and TXN at 51.47.
Which has grown faster, AZN or TXN?: Over the past five years, AZN grew revenue faster — AZN at a 16.99% CAGR versus TXN at 3.64%.
Does AZN or TXN pay a bigger dividend?: AZN yields 1.79% and TXN yields 1.87% based on trailing dividends and the latest price.
Is AZN or TXN more profitable?: TXN runs the higher net margin — AZN at 17.19% versus TXN at 29.11%.
Which has been the better investment, AZN or TXN?: Over the past 10-year, TXN delivered the higher annualized total return — AZN at 15.77% versus TXN at 20.37%. Past performance doesn't predict future results.

Go deeper

Full AZN analysis Full TXN analysis Interactive comparison tool

Dig into the metrics

AstraZeneca P/E ratio Texas Instruments P/E ratio AstraZeneca dividend yield Texas Instruments dividend yield AstraZeneca ROE Texas Instruments ROE AstraZeneca operating margin Texas Instruments operating margin AstraZeneca revenue growth Texas Instruments revenue growth AstraZeneca free cash flow Texas Instruments free cash flow

AstraZeneca & Texas Instruments appear in these rankings

Fastest Revenue Growth Stocks Highest ROE Stocks Highest Operating Margin Stocks Best 10-Year Total Return Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified June 15, 2026.